GOSS

Gossamer Bio Inc

NASDAQ

Add Alert

GOSS

Gossamer Bio Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

FlippinNDippin Free

04/09/24 7:04 PM

Post #14

Took a starter here. GLTA

Monksdream PremiumMember

03/17/24 11:27 AM

Post #13

GOSS under $2

glenn1919

03/16/24 9:28 AM

Post #12

GOSS..........................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783

glenn1919

02/24/24 10:04 AM

Post #11

GOSS..................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783

glenn1919

02/19/24 1:53 PM

Post #10

GOSS......................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783

Monksdream PremiumMember

02/19/24 1:38 PM

Post #9

GOSS under $2

Monksdream PremiumMember

09/24/23 12:11 PM

Post #8

GOSS new 52 week low

Monksdream PremiumMember

09/17/23 2:34 PM

Post #7

GOSS new 52 week low

Monksdream PremiumMember

09/14/23 2:53 PM

Post #6

GOSS new 52 week low

Dutch4

03/24/23 1:03 PM

Post #5

Re: #3: @hippityhop - This is a 100/200 percenter in next 3

Agreed!

hippityhop Free

12/22/22 4:20 PM

Post #4

Institutionals shorting this unmercilessly. Three trades totalling 2.4M total shares bought at 4 pm. @ .20 cent profit a share come to $468k.

hippityhop Free

12/19/22 11:53 AM

Post #3

This is a 100/200 percenter in next 3 months, buy this now or weep later!!

crudeoil24 PremiumMember

04/20/22 7:43 PM

Post #2

Raymond James Initiates Coverage On Gossamer Bio with Outperform Rating, Announces Price Target of $19
7:13 am ET April 18, 2022 (Benzinga) Print
Raymond James analyst Timur Ivannikov initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $19.

Latest Ratings for GOSS DateFirmActionFromTo

Nov 2021SVB LeerinkMaintainsOutperform Aug 2021SVB LeerinkMaintainsOutperform Mar 2021HC Wainwright & Co.ReiteratesBuy

crudeoil24 PremiumMember

04/20/22 7:41 PM

Post #1

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).